AsiaIntervention最新文献_第4页

Interventional cardiology: a 2023 recap and what to expect in 2024. 介入心脏病学：2023 年回顾与 2024 年展望。

AsiaIntervention Pub Date : 2024-02-29 eCollection Date: 2024-02-01 DOI: 10.4244/AIJ-E-23-00006

Mirvat Alasnag, Mognee Alameer

引用次数: 0

Percutaneous device closure of left ventricular pseudoaneurysm: a rare case. 经皮设备闭合左心室假性动脉瘤：一例罕见病例。

AsiaIntervention Pub Date : 2024-02-29 eCollection Date: 2024-02-01 DOI: 10.4244/AIJ-D-22-00073

Mahendrasingh Parihar, Sachin Mukhedkar, Ajit Bhagwat

引用次数: 0

First-in-Asia native valve modified-BASILICA TAVR with CT fusion, complicated by annular rupture rescued with coil embolisation. 亚洲首例原生瓣膜改良-BASILICA TAVR，CT融合，瓣环破裂并发线圈栓塞抢救。

AsiaIntervention Pub Date : 2024-02-29 eCollection Date: 2024-02-01 DOI: 10.4244/AIJ-D-23-00026

Michael Chiang, Ivan Wong, Shing Fung Chui, Chi Yuen Eric Wong, Pedro A Villablanca, Michael Kang-Yin Lee

引用次数: 0

Three-dimensional multiplanar reconstruction by transoesophageal echocardiography showed inside reverse fold: "origami" shape of WATCHMAN FLX. 经食道超声心动图的三维多平面重建显示了 WATCHMAN FLX 内部的反向折叠："折纸 "形状。

AsiaIntervention Pub Date : 2024-02-29 eCollection Date: 2024-02-01 DOI: 10.4244/AIJ-D-23-00032

Tadatomo Fukushima, Masato Fukunaga, Akihiro Isotani, Shinichi Shirai, Kenji Ando

引用次数: 0

A 2024 scientific update on the clinical performance of drug-coated balloons. 2024 年药物涂层球囊临床表现的科学更新。

AsiaIntervention Pub Date : 2024-02-29 eCollection Date: 2024-02-01 DOI: 10.4244/AIJ-D-23-00010

Florin-Leontin Lazar, Horea-Laurentiu Onea, Dan-Mircea Olinic, Bernardo Cortese

{"title":"A 2024 scientific update on the clinical performance of drug-coated balloons.","authors":"Florin-Leontin Lazar, Horea-Laurentiu Onea, Dan-Mircea Olinic, Bernardo Cortese","doi":"10.4244/AIJ-D-23-00010","DOIUrl":"10.4244/AIJ-D-23-00010","url":null,"abstract":"Continuous advances in the field of interventional cardiology have led to the development of drug-coated balloons (DCB). These represent a promising device for overcoming the well-known limitations of traditional metallic stents, which are associated with a persistent yearly increased risk of adverse events. This technology has the ability to homogeneously transfer the drug into the vessel wall in the absence of a permanent prosthesis implanted in the coronary vessel. Robust data support the use of DCB for the treatment of in-stent restenosis, but there is also currently growing evidence from long-term follow-up of large randomised clinical trials regarding the use of these devices in other scenarios, such as de novo small and large vessel disease, complex bifurcations, and diffuse coronary disease. Other critical clinical settings such as diabetes mellitus, high bleeding risk patients and acute coronary syndromes could be approached in the upcoming future by using DCB, alone or as part of a blended strategy in combination with drug-eluting stents. There have been important scientific and technical advances in the DCB field in recent years. The purpose of this paper is to review the most current data regarding the use of DCB, including the mid- and long-term follow-up reports on the safety and efficacy of this novel strategy in different clinical and angiographic scenarios.","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10900242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modified proximal optimisation technique for long left main interventions to prevent stent elongation. 针对长左主干介入治疗的改良近端优化技术，以防止支架拉长。

AsiaIntervention Pub Date : 2024-02-29 eCollection Date: 2024-02-01 DOI: 10.4244/AIJ-D-23-00034

Himanshu Gupta, Navjyot Kaur, Pruthvi C Revaiah

引用次数: 0

Attention when performing transcatheter valve-in-valve procedures in degenerative INSPIRIS RESILIA valves: a case of malfunction in the expansion zone. 在退行性INSPIRIS RESILIA瓣膜中进行经导管瓣膜置换术时应注意：一例扩张区出现故障。

AsiaIntervention Pub Date : 2023-09-21 eCollection Date: 2023-09-01 DOI: 10.4244/AIJ-D-22-00079

Hirofumi Hioki, Yusuke Watanabe, Akihisa Kataoka, Hideyuki Kawashima, Ken Kozuma

引用次数: 0

New opportunities for bioresorbable scaffold technology. 生物可吸收支架技术的新机遇。

AsiaIntervention Pub Date : 2023-09-21 eCollection Date: 2023-09-01 DOI: 10.4244/AIJ-E-23-00003

Adnan Kastrati, Masaru Seguchi

引用次数: 0

Obstructive sleep apnoea and coronary revascularisation outcomes. 阻塞性睡眠呼吸暂停和冠状动脉血运重建结果。

AsiaIntervention Pub Date : 2023-09-21 eCollection Date: 2023-09-01 DOI: 10.4244/AIJ-D-22-00089

Adrienne Yh Chew, Chi-Hang Lee

{"title":"Obstructive sleep apnoea and coronary revascularisation outcomes.","authors":"Adrienne Yh Chew, Chi-Hang Lee","doi":"10.4244/AIJ-D-22-00089","DOIUrl":"10.4244/AIJ-D-22-00089","url":null,"abstract":"Obstructive sleep apnoea (OSA) is a chronic sleep disorder characterised by recurrent cyclical episodes of upper airway collapse causing apnoea or hypopnoea. Despite being highly prevalent in patients with cardiovascular conditions, OSA has been a neglected component in cardiovascular practice. Fortunately, in the past few decades, increasing acknowledgement of the vulnerability of cardiac patients to OSA-related stressors and its adverse cardiovascular outcomes has made it a recognised cardiovascular risk factor in practice guidelines. Consequences of OSA include oxidative stress, endothelial dysfunction, autonomic dysfunction, and increased catecholamine release. The perturbations caused by OSA not only provide a clear mechanistic link to cardiovascular disease but also to poor outcomes after coronary revascularisation. This review article focuses on the correlation of OSA to coronary revascularisation outcomes. Our team reported that OSA is present in approximately 50% of patients undergoing coronary revascularisation. Importantly, untreated OSA was found to be an independent predictor of adverse events after both percutaneous coronary intervention and coronary artery bypass grafting. Although randomised trials did not confirm the benefits of OSA treatment in improving cardiovascular outcomes, these early trials were limited by poor treatment adherence. For now, systematic screening for OSA in patients undergoing coronary revascularisation is not indicated. Yet, with the proven benefit of OSA treatment in improving blood pressure control and quality of life, screening for and treatment of OSA is still indicated if patients have reported excessive daytime sleepiness and/or suboptimally controlled hypertension.","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507609/pdf/AIJ-D-22-00089_Chew.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41173362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sharing knowledge and defining partnerships across boundaries through AICT-AsiaPCR. 通过AICT AsiaPCR分享知识并确定跨国界伙伴关系。

AsiaIntervention Pub Date : 2023-09-21 eCollection Date: 2023-09-01 DOI: 10.4244/AIJ-E-23-00004

Ashok Seth

引用次数: 0